Compare Enveric Biosciences Inc (ENVB) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while iShares Core MSCI Emerging Markets ETF trades at $81.16 (market cap $162.00B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 23823.5× Enveric Biosciences Inc's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares Core MSCI Emerging Markets ETF for 57 Days on average.
| ENVB | IEMG | |
|---|---|---|
Market Cap | $6.80M | $162.00B |
Volume | 64,867 | 13,446,151 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $86.00 |
52-Week Low | $1.27 | $64.22 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
IEMG trades at $81.14, down 1.1% with a bearish technical signal from moving averages. The ETF's emerging markets focus has delivered strong recent performance, with articles highlighting 35% one-year returns and record asset inflows. Technical indicators show neutral oscillators but bearish momentum, with key support at $79 and resistance at $82.
Emerging markets exposure offers growth potential amid dollar weakness, though higher volatility and expense ratios compared to developed market ETFs present risks. The fund's 39% technology weighting and outperformance versus peers like SCHE and VWO provide differentiation, but concentration risks and market sensitivity require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
